FDA Approves VariZIG for Reducing Chickenpox Infections

FDA Approves VariZIG for Reducing Chickenpox Infections Posted 1/8/13
The US Food and Drug Administration (FDA) recently approved VariZIG, a varicella zoster immune globulin preparation, for reducing the severity of chickenpox (varicella zoster virus [VZV]) infections in high risk individuals. Infection severity is reduced when VariZIG is given within 96 hours of exposure to VZV.

While most people in the US have immunity to VZV from having received vaccination or from having had chickenpox, people with no immunity may experience severe infections if exposed to VZV. VariZIG is approved for immune-compromised children and adults, pregnant women, premature infants, newborns, children younger than one year of age, and adults with no immunity to VZV.

To read the full news release and additional information, please visit the FDA web site.

For additional information on varicella zoster infection, please see the Varicella-Zoster Infections chapter on Red Book Online.

hello,

celebrated new year's day in Turkey. I  celebrated with my family at home.  We have made the party with my son and sweet girl. And my sister that is constantly with us. I am working in a private hospital. I'm glad my work. I love all the kids.   

I'am a pediatrician and mom in Turkey. I have my two kids. It is one of the 6-year-old boy and the other is 8 months my daughter. I'll share share obout both the mother and the doctor.